Literature DB >> 26839260

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

David H Munn1, Andrew L Mellor2.   

Abstract

Indoleamine 2,3-dioxygenase (IDO) has immunoregulatory roles associated with tryptophan metabolism. These include counter-regulation (controlling inflammation) and acquired tolerance in T cells. Recent findings reveal that IDO can be triggered by innate responses during tumorigenesis, and also by attempted T cell activation, either spontaneous or due to immunotherapy. Here we review the current understanding of mechanisms by which IDO participates in the control of inflammation and in peripheral tolerance. Focusing on the tumor microenvironment, we examine the role of IDO in response to apoptotic cells and the impact of IDO on Treg cell function. We discuss how the counter-regulatory and tolerogenic functions of IDO can be targeted for cancer immunotherapy and present an overview of the current clinical progress in this area.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26839260      PMCID: PMC4916957          DOI: 10.1016/j.it.2016.01.002

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  124 in total

1.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

2.  Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

Authors:  Soranobu Ninomiya; Neeharika Narala; Leslie Huye; Shigeki Yagyu; Barbara Savoldo; Gianpietro Dotti; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Carlos A Ramos
Journal:  Blood       Date:  2015-05-04       Impact factor: 22.113

3.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

4.  Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.

Authors:  Holly K Koblish; Michael J Hansbury; Kevin J Bowman; Gengjie Yang; Claire L Neilan; Patrick J Haley; Timothy C Burn; Paul Waeltz; Richard B Sparks; Eddy W Yue; Andrew P Combs; Peggy A Scherle; Kris Vaddi; Jordan S Fridman
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

5.  Modulation of tryptophan catabolism by regulatory T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Kwang Woo Hwang; Ciriana Orabona; Carmine Vacca; Roberta Bianchi; Maria Laura Belladonna; Maria Cristina Fioretti; Maria-Luisa Alegre; Paolo Puccetti
Journal:  Nat Immunol       Date:  2003-10-26       Impact factor: 25.606

6.  Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease.

Authors:  Luigina Romani; Francesca Fallarino; Antonella De Luca; Claudia Montagnoli; Carmen D'Angelo; Teresa Zelante; Carmine Vacca; Francesco Bistoni; Maria C Fioretti; Ursula Grohmann; Brahm H Segal; Paolo Puccetti
Journal:  Nature       Date:  2008-01-10       Impact factor: 49.962

7.  IDO and regulatory T cell support are critical for cytotoxic T lymphocyte-associated Ag-4 Ig-mediated long-term solid organ allograft survival.

Authors:  Robert Sucher; Klaus Fischler; Rupert Oberhuber; Irmgard Kronberger; Christian Margreiter; Robert Ollinger; Stefan Schneeberger; Dietmar Fuchs; Ernst R Werner; Katrin Watschinger; Bettina Zelger; George Tellides; Nina Pilat; Johann Pratschke; Raimund Margreiter; Thomas Wekerle; Gerald Brandacher
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

8.  Structural mechanism of cytosolic DNA sensing by cGAS.

Authors:  Filiz Civril; Tobias Deimling; Carina C de Oliveira Mann; Andrea Ablasser; Manuela Moldt; Gregor Witte; Veit Hornung; Karl-Peter Hopfner
Journal:  Nature       Date:  2013-05-30       Impact factor: 49.962

9.  Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes.

Authors:  Maria Teresa Pallotta; Ciriana Orabona; Roberta Bianchi; Carmine Vacca; Francesca Fallarino; Maria Laura Belladonna; Claudia Volpi; Giada Mondanelli; Marco Gargaro; Massimo Allegrucci; Vincenzo Nicola Talesa; Paolo Puccetti; Ursula Grohmann
Journal:  J Cell Mol Med       Date:  2014-09-12       Impact factor: 5.310

10.  The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.

Authors:  Minghui Li; Aaron R Bolduc; Md Nasrul Hoda; Denise N Gamble; Sarah-Bianca Dolisca; Anna K Bolduc; Kelly Hoang; Claire Ashley; David McCall; Amyn M Rojiani; Bernard L Maria; Olivier Rixe; Tobey J MacDonald; Peter S Heeger; Andrew L Mellor; David H Munn; Theodore S Johnson
Journal:  J Immunother Cancer       Date:  2014-07-07       Impact factor: 13.751

View more
  306 in total

1.  Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells.

Authors:  Min-Hee Oh; Im-Hong Sun; Liang Zhao; Robert D Leone; Im-Meng Sun; Wei Xu; Samuel L Collins; Ada J Tam; Richard L Blosser; Chirag H Patel; Judson M Englert; Matthew L Arwood; Jiayu Wen; Yee Chan-Li; Lukáš Tenora; Pavel Majer; Rana Rais; Barbara S Slusher; Maureen R Horton; Jonathan D Powell
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

Review 2.  Inhibitors of the PD-1 Pathway in Tumor Therapy.

Authors:  Martin W LaFleur; Yuki Muroyama; Charles G Drake; Arlene H Sharpe
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.

Authors:  Zhuoya Wan; Jingjing Sun; Jieni Xu; Pearl Moharil; Jing Chen; Junchi Xu; Junjie Zhu; Jiang Li; Yixian Huang; Pengfei Xu; Xiaochao Ma; Wen Xie; Binfeng Lu; Song Li
Journal:  Acta Biomater       Date:  2019-03-28       Impact factor: 8.947

Review 4.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

5.  Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

Authors:  Zachary J Brown; Su Jong Yu; Bernd Heinrich; Chi Ma; Qiong Fu; Milan Sandhu; David Agdashian; Qianfei Zhang; Firouzeh Korangy; Tim F Greten
Journal:  Cancer Immunol Immunother       Date:  2018-06-29       Impact factor: 6.968

6.  Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening.

Authors:  Hongao Zhang; Wei Liu; Zhihong Liu; Yingchen Ju; Mengyang Xu; Yue Zhang; Xinyu Wu; Qiong Gu; Zhong Wang; Jun Xu
Journal:  Medchemcomm       Date:  2018-03-01       Impact factor: 3.597

Review 7.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

Review 8.  Targeted Metabolic Reprogramming to Improve the Efficacy of Oncolytic Virus Therapy.

Authors:  Barry E Kennedy; Maryanne Sadek; Shashi A Gujar
Journal:  Mol Ther       Date:  2020-03-20       Impact factor: 11.454

Review 9.  Mechanisms of Resistance to PD-1 Checkpoint Blockade.

Authors:  Justin C Moser; Siwen Hu-Lieskovan
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

10.  IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.

Authors:  Weili Wang; Lei Huang; Jian-Yue Jin; Shruti Jolly; Yong Zang; Huanmei Wu; Li Yan; Wenhu Pi; Lang Li; Andrew L Mellor; Feng-Ming Spring Kong
Journal:  Cancer Res       Date:  2017-11-08       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.